Enhanced Vector Bioprocessing Technologies for Cell and Gene Therapies
Lead Participant:
SYNPROMICS LTD
Abstract
Evolving therapeutic approaches of cell and gene therapy are harnessing the power of viruses in order to
modify genomes of cells to produce a therapeutic effect. Such therapies are starting to show efficacy in the
clinic, but one of the key challenges to their widespread use is the ability to make large quantities of virus at a
low cost. This project seeks to address this challenge by creating new methods of producing large quantities of
virus at a low cost. It brings together Synpromics, a synthetic biology company based in Edinburgh, and the Cell
Therapy Catapult, one of the UK’s network of Catapult centres focused on developing and growing a cell and
gene therapy industry in the UK.
modify genomes of cells to produce a therapeutic effect. Such therapies are starting to show efficacy in the
clinic, but one of the key challenges to their widespread use is the ability to make large quantities of virus at a
low cost. This project seeks to address this challenge by creating new methods of producing large quantities of
virus at a low cost. It brings together Synpromics, a synthetic biology company based in Edinburgh, and the Cell
Therapy Catapult, one of the UK’s network of Catapult centres focused on developing and growing a cell and
gene therapy industry in the UK.
Lead Participant | Project Cost | Grant Offer |
---|---|---|
SYNPROMICS LTD | £1,387,753 | £ 971,427 |
  | ||
Participant |
||
CELL THERAPY CATAPULT LIMITED | £606,297 | £ 606,297 |
THE NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST |
People |
ORCID iD |
Kirsten Young (Project Manager) |